GIP activation enhances insulin secretion while potentially improving the tolerability of the medication
Phosphoenolpyruvate carboxykinase 1 (PCK1), as a key enzyme in gluconeogenesis, can increase the production of PEP in T cells, improve glucose uptake, and enhance its immune effects
The timing of this announcement is critical, coming shortly after Novo Nordisk revealed disappointing results for its next-generation obesity drug, CagriSema
Results Included Studies Figure 1 was the retrieval process and a total of 10 RCT studies, comprising 1,239 T2DM patients were included for analysis, including 8 studies of l-carnitine (916), 1 study of acetyl-l-carnitine (17), and 1 study of propionyl-l-carnitine (18)
Vulnerability factors such as genetic predisposition, initial drug exposure, and social environment also play critical roles
This medication requires daily injections rather than weekly ones